Farewell to Chris Richardson

Chris Richardson joined the lab as a Postdoctoral Fellow in July 2014 and made huge advances in human gene editing. He developed new ways to improve NHEJ and HDR, plus discovered out that genome editing in human cells works via the Fanconi Anemia Pathway. Three major first author papers in three years – not bad! Chris will be joining Spotlight Therapeutics as a Group Leader, and may have some additional career news to share soon. We wish you success in all your future endeavors!

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest News

March 31, 2026

Welcome back to Camilla!

Camilla Micheli obtained her Bachelor’s degree in Biology from Maastricht University (UM) in 2024. She is currently enrolled in the Microbiology and Immunology...

March 26, 2026

DisTAL-Seq: A NEW METHOD TO PROFILE TALEN OFF-TARGETS — PUBLISHED IN MOLECULAR THERAPY: NUCLEIC ACIDS

Programmable nucleases have transformed genome editing, enabling precise DNA modification for both research and therapeutic applications. However, ...

March 16, 2026

SP110 PROTECTS CELLS FROM INTEREFERON-INDUCED CELL DEATH- PUBLISHED IN NATURE CELL BIOLOGY

Stimulation of the innate immune system by foreign RNA triggers a strong interferon response that helps cells defend against infection. However, this powerful...

News Archive

Tweets